---

Physiological Changes in Pregnancy by Trimester

---

🫀 Cardiovascular System

• CO increases starting at 6 weeks due to progesterone-mediated vasodilation and increased estrogen driving plasma volume expansion.
• Uterine blood flow increases from ~50 mL/min at 10 weeks to ~500–750 mL/min at term.
• Aortocaval compression by the gravid uterus after 20 weeks can reduce CO in the supine position (relieved by left lateral decubitus).

---

🩸 Hematological Changes

• The disproportionate rise in plasma vs. red cell mass creates physiological anemia of pregnancy.
• The hypercoagulable state (↑ procoagulants, ↓ anticoagulants) protects against hemorrhage at delivery but increases VTE risk 4–5x.

---

🫁 Respiratory System

• Progesterone directly stimulates the respiratory center → chronic respiratory alkalosis with renal compensation.
• Dyspnea is reported in ~70% of pregnancies even without pathology (due to increased ventilatory drive).
• Capillary engorgement of upper airway mucosa → nasal congestion, epistaxis, difficult intubation.

---

🫘 Renal System

• Renal sodium reabsorption increases to maintain ECF expansion despite high GFR.
• Ureteral dilation (hydroureteronephrosis) is due to progesterone-mediated smooth muscle relaxation + uterine compression → increased UTI risk.
• Creatinine and BUN are lower; values considered "normal" outside pregnancy may indicate renal impairment in pregnancy.

---

🦠 Gastrointestinal System

• Nausea and vomiting (1st trimester) are mediated by hCG peaking at 8–10 weeks.
• Increased gastric pressure from the gravid uterus worsens GERD in the 3rd trimester.

---

⚗️ Endocrine System

Thyroid

• Thyroid-binding globulin (TBG) ↑ → total T3 and T4 ↑, but free T4 and T3 remain normal.
• hCG (structural similarity to TSH) → mild thyroid stimulation in 1st trimester → TSH transiently ↓.
• Iodine requirements ↑; iodine clearance ↑.

Adrenal

• Cortisol ↑ (CBG increases; free cortisol also slightly ↑ — physiological hypercortisolism).
• Aldosterone ↑ significantly to maintain sodium balance.

Pancreas / Glucose Metabolism

• Human placental lactogen (hPL/HPL), progesterone, cortisol, and prolactin all antagonize insulin → progressive insulin resistance favoring fetal glucose supply.
• Fasting hypoglycemia can occur in 1st trimester (glucose diverted to fetus).

Pituitary

• Pituitary enlarges up to 135% (mainly prolactin-secreting cells).
• Prolactin ↑ progressively (up to 200 ng/mL at term).
• GH secretion from pituitary is suppressed; placental GH takes over.

---

🦴 Musculoskeletal System

• Relaxin (peaks at 12 weeks, then again at term) → ligamentous laxity throughout the body.
• Pubic symphysis widens (~3–4 mm normally, pathological if >10 mm).
• Sacroiliac joint mobility ↑ → lower back pain.
• Center of gravity shifts forward → lumbar lordosis increases → lordotic posture.
• Diastasis recti abdominis (separation of rectus muscles) develops in 3rd trimester.

---

🧴 Skin & Integumentary

---

🧠 Neurological & Posture

• Mild cognitive changes (forgetfulness — "pregnancy brain") due to hormonal shifts and sleep disruption.
• Carpal tunnel syndrome in 3rd trimester (fluid retention compresses median nerve).
• Meralgia paresthetica (lateral femoral cutaneous nerve compression).

---

📊 Summary: Key Lab Value Changes in Pregnancy

---

---

Conditions Where FSH is Low

---

🧠 Mechanism of FSH Regulation

Hypothalamus → GnRH (pulsatile)
        ↓
Anterior Pituitary → FSH + LH
        ↓
Gonads → Sex steroids (Estrogen/Testosterone) + Inhibin B
        ↓ (negative feedback)
Hypothalamus + Pituitary ← suppressed

---

📋 Classification of Conditions Causing Low FSH

---

1. 🧠 Hypothalamic Causes (↓ GnRH → ↓ FSH + LH)

A. Functional Hypothalamic Amenorrhea / Anovulation

• Most common cause of low FSH in reproductive-age women
• Triggered by:
  • Excessive exercise (female athlete triad)
  • Caloric restriction / anorexia nervosa / malnutrition
  • Psychological stress
• FSH is low-normal or low; LH pulsatility is disrupted
• Reversible with restoration of body weight/stress reduction

B. Kallmann Syndrome

• Congenital GnRH deficiency + anosmia (absent sense of smell)
• X-linked (KAL1/ANOS1 gene) or autosomal (FGFR1, PROKR2 mutations)
• Presents as complete absence of puberty, sexual infantilism
• FSH and LH both very low/undetectable (Harrison's, p. 10973)

C. Idiopathic Hypogonadotropic Hypogonadism (IHH)

• Same as Kallmann but without anosmia
• GnRH neuron migration or secretion defect
• FSH + LH low; testosterone/estrogen low

D. Hypothalamic Tumors / Infiltrative Disease

• Craniopharyngioma — most common hypothalamic tumor causing HH
• Germinoma, glioma, hamartoma
• Infiltrative: sarcoidosis, histiocytosis X (Langerhans cell histiocytosis), tuberculosis, hemochromatosis
• Radiation to hypothalamus

---

2. 🫐 Pituitary Causes (Direct gonadotrope failure → ↓ FSH)

A. Hyperprolactinemia

• PRL inhibits hypothalamic GnRH secretion via dopaminergic pathways; may also destroy gonadotropes via tumor mass effect
• Causes:
  • Prolactinoma (most common pituitary tumor)
  • Drugs (dopamine antagonists: antipsychotics, metoclopramide, domperidone)
  • Hypothyroidism (↑ TRH → ↑ PRL)
  • Renal failure, chest wall lesions
• FSH and LH both suppressed; treatment with dopamine agonists reverses deficiency (Harrison's, p. 10982)

B. Pituitary Tumors (Non-functioning or Functioning)

• Mass effect compresses gonadotropes
• GH-secreting (acromegaly), ACTH-secreting (Cushing's disease), or non-functioning adenomas
• Pituitary carcinoma (rare)

C. Sheehan's Syndrome

• Postpartum pituitary necrosis due to ischemia (massive obstetric hemorrhage)
• Panhypopituitarism; FSH/LH among first to be lost
• Presents with failure of lactation, amenorrhea, hypothyroidism, adrenal insufficiency

D. Pituitary Apoplexy

• Acute hemorrhage or infarction into a pituitary adenoma
• Sudden-onset headache, visual loss, panhypopituitarism
• Emergency

E. Empty Sella Syndrome

• Herniation of subarachnoid space into sella → pituitary compression
• Primary or secondary (post-surgery/radiation)
• Variable hormone deficiencies including low FSH

F. Pituitary Infiltrative/Inflammatory Disease

• Lymphocytic hypophysitis (autoimmune; common peripartum)
• Sarcoidosis, tuberculosis, hemochromatosis involving pituitary
• Radiation-induced hypopituitarism (delayed; dose-dependent)

G. Isolated FSH Deficiency

• Very rare; mutations in FSH-β subunit gene
• Women: amenorrhea, infertility; Men: azoospermia

---

3. 📉 Negative Feedback / Suppression States

A. Pregnancy

• High estrogen + progesterone + hCG → strong negative feedback → FSH suppressed throughout pregnancy
• Physiological; FSH normalizes postpartum

B. Exogenous Sex Steroids / Hormonal Contraceptives

• Combined oral contraceptive pills (COCPs), hormone replacement therapy, anabolic steroids
• Testosterone therapy in men → suppress FSH via negative feedback
• Anabolic steroid abuse — major cause of low FSH + LH + testosterone in men (despite normal/high androgens)

C. Ovarian / Testicular Hypersecretion

• Estrogen-secreting tumors (granulosa cell tumor) → suppress FSH
• Testosterone-secreting tumors (Leydig cell tumor, adrenal tumor)
• Congenital adrenal hyperplasia (CAH) — excess androgens suppress HPG axis

D. High Inhibin B / Inhibin A States

• Granulosa cell tumors secrete inhibin → selectively suppress FSH (LH may be normal)
• Used as tumor marker

---

4. 🔁 Systemic / Chronic Illness

---

5. 🧒 Special Populations

Prepubertal Children (Normal)

• FSH is physiologically low before puberty — not pathological.

Constitutional Delay of Growth and Puberty (CDGP)

• Delayed but ultimately normal puberty
• Temporarily low FSH/LH; bone age delayed
• Distinguished from true HH by GnRH stimulation test

---

🔬 Diagnostic Approach to Low FSH

Low FSH confirmed
        │
        ├─ Check LH, testosterone/estradiol, prolactin, TSH
        │
        ├─ PRL elevated? → Prolactinoma / drug-induced / hypothyroidism
        │
        ├─ MRI pituitary/hypothalamus
        │       → Tumor, empty sella, infiltration
        │
        ├─ Anosmia? → Kallmann syndrome
        │
        ├─ BMI low / extreme exercise / stress?
        │       → Functional hypothalamic HH
        │
        ├─ Exogenous steroids / opioids?
        │       → Drug-induced suppression
        │
        └─ GnRH stimulation test
                → Differentiates hypothalamic vs. pituitary cause

---

📊 Quick Reference Summary

---

---

Transverse Vaginal Septum (TVS)

🧬 Embryology & Pathogenesis

1. Upper 2/3 — from the Müllerian (paramesonephric) ducts, which fuse to form the uterovaginal canal.
2. Lower 1/3 — from the urogenital sinus (sinovaginal bulbs), which proliferate upward as the vaginal plate.

• Failure of complete canalization of the vaginal plate, OR
• Failure of fusion between the Müllerian duct-derived upper vagina and the urogenital sinus-derived lower vagina at their junction

---

📍 Location & Classification

By Location

Higher septum = thicker septum = more difficult surgery and worse prognosis for fertility.

By Morphology

---

🔬 MRI Appearance

---

🏥 Clinical Presentation

Neonatal Period

• Usually identified incidentally or if mucocolpos (mucus accumulation) causes a palpable pelvic mass or urinary obstruction.

Adolescence (Most Common Presentation)

• Primary amenorrhea with cyclic pelvic pain (cryptomenorrhea) — classic
• Hematocolpos — blood accumulates below septum → lower abdominal mass
• Hematometra — blood accumulates in uterus if long-standing
• Hematosalpinx — retrograde filling of fallopian tubes
• Possible urinary symptoms (retention, frequency) from mass compression
• Endometriosis (from retrograde menstruation) is a long-term complication

Reproductive Age (Incomplete Septum)

• Dyspareunia — painful intercourse
• Infertility or recurrent pregnancy loss
• Difficulty with tampon insertion
• Abnormal vaginal bleeding patterns
• May only be diagnosed during gynecological examination or infertility workup

---

🆚 Differential Diagnosis

---

🔍 Diagnosis

Clinical Examination

• Inspection: Normal external genitalia and hymen (unlike imperforate hymen)
• Speculum/digital exam: Blind-ending vaginal pouch; cervix not visualized
• In complete TVS: vault appears smooth with no cervix visible

Imaging

MRI is critical — it measures:

• Distance from introitus to inferior septum (determines surgical approach)
• Septum thickness (predicts surgical difficulty)
• Upper vaginal length (predicts functional outcome)

---

🔧 Management

Surgical Correction — Excision of the Septum

Surgical Principles

1. Excision of the septal tissue (not just incision — to prevent re-stenosis)
2. Re-anastomosis of upper and lower vaginal segments
3. Primary closure with interrupted absorbable sutures
4. Vaginal stenting/dilation postoperatively to prevent re-stenosis

Approach Based on Location

Key Surgical Steps (Transvaginal Approach)

1. Identify the septum
2. Aspirate hematocolpos (if present) to decompress and identify the upper vagina
3. Cruciate incision in the septum → excise septal ring completely
4. Mobilize upper and lower vaginal walls
5. End-to-end anastomosis
6. Insert vaginal stent/mold postoperatively (worn for weeks to months)

Postoperative Care

• Vaginal dilators — used regularly to maintain patency and prevent restenosis (critical especially for high septa)
• Follow-up examinations to confirm patency
• Psychological support and counseling

---

⚕️ Complications

If Untreated

• Progressive hematocolpos → hematometra → hematosalpinx
• Endometriosis (retrograde menstruation) — significantly impairs fertility
• Pelvic adhesions
• Pyocolpos (infected collection)
• Renal anomalies (associated in some cases)

Post-Surgical

• Restenosis / re-obstruction — most important complication, especially with high septa
• Dyspareunia
• Infertility (reduced fertility with high septa despite surgery)
• Wound dehiscence

---

🤰 Fertility Outcomes

• Early diagnosis and surgery before endometriosis develops significantly improves fertility.
• Pregnancy rates after surgical correction range from 25–50% depending on septum level and extent of associated disease.

---

🔗 Associated Anomalies

• Renal anomalies (horseshoe kidney, renal agenesis) — due to shared embryological origin with mesonephric system
• Longitudinal vaginal septum
• Uterine anomalies (septate/bicornuate uterus)
• Ovarian dysgenesis (rare)

---

📝 Summary

---

Investigation of Primary Amenorrhea — Step-by-Step Approach

📌 Definition & When to Investigate

---

🧭 Overview of the Approach

1. Are secondary sexual characteristics (breasts, pubic hair) present? → Reflects estrogen/androgen action
2. Is the uterus present? → Reflects Müllerian development

---

🔢 Step-by-Step Investigation

---

✅ STEP 1 — History & Physical Examination

• Age of onset of any pubertal signs
• Cyclic pelvic pain (suggests outflow obstruction with functional uterus)
• Anosmia (Kallmann syndrome)
• Headaches, visual field defects (pituitary tumor)
• Weight changes, exercise habits, stress (functional hypothalamic amenorrhea)
• Drug history (antipsychotics, chemotherapy, steroids)
• Family history of delayed puberty or amenorrhea
• Symptoms of hypothyroidism, Cushing's, chronic illness

• Height, weight, BMI
• Turner stigmata: short stature, webbed neck, wide-carrying angle, shield chest, low hairline
• Breast development (Tanner staging) — reflects estrogen
• Pubic/axillary hair (Tanner staging) — reflects androgens
• External genitalia: clitoromegaly, labial fusion, hymenal appearance
• Vaginal examination: depth, presence of cervix, blind vaginal pouch
• Thyroid palpation
• Signs of hyperandrogenism (acne, hirsutism)
• Signs of galactorrhea (→ hyperprolactinemia)

---

✅ STEP 2 — Pregnancy Test

• β-hCG (urine or serum) — must be excluded first in any woman of reproductive age regardless of history.

---

✅ STEP 3 — Assess Secondary Sexual Characteristics

---

🔵 BRANCH A: No Breast Development (No Estrogen Effect)

• 45,X → Turner syndrome (most common cause of gonadal dysgenesis)
• 46,XX → Pure gonadal dysgenesis (Swyer if XY)
• 46,XY → Swyer syndrome (46,XY gonadal dysgenesis)
• Mosaic patterns (45,X/46,XX etc.)

• Kallmann syndrome (+ anosmia)
• Idiopathic hypogonadotropic hypogonadism (IHH)
• Pituitary tumors (craniopharyngioma, prolactinoma)
• Hypothalamic infiltrative disease
• Constitutional delay (diagnosis of exclusion)

---

🔴 BRANCH B: Breast Development Present (Estrogen Present)

---

🔴 Branch B1: Uterus Absent on USS

• Karyotype (46,XX vs. 46,XY) — essential
• Testosterone (male range in AIS, female range in MRKH)
• Pelvic MRI — confirm absence of uterus, locate gonads
• Renal USS in MRKH (30–40% have renal anomalies)

---

🔴 Branch B2: Uterus Present on USS

• Uterus is present and functional → menstrual blood cannot exit
• Cyclic pelvic pain ± hematocolpos is characteristic

• Imperforate hymen — membrane at vaginal introitus; bulging, bluish with Valsalva
• Transverse vaginal septum — intravaginal; normal hymen visible
• Cervical agenesis/stenosis — rare; uterus present, no cervix
• Vaginal agenesis with functional uterus — rare variant

---

✅ STEP 4 — Additional Hormonal Workup (All Branches)

---

✅ STEP 5 — Imaging

---

✅ STEP 6 — Karyotype

• No breast development
• Absent uterus
• Any suspicion of gonadal dysgenesis
• Short stature with Turner features
• Male-range testosterone

---

🗺️ Investigation Algorithm at a Glance

Primary Amenorrhea
        │
        ├─ β-hCG → Exclude pregnancy
        │
        ├─ SECONDARY SEXUAL CHARACTERISTICS?
        │
        ├─ NO BREASTS (No estrogen)
        │       │
        │       ├─ FSH/LH HIGH → Gonadal failure
        │       │       └─ Karyotype:
        │       │               45,X  → Turner syndrome
        │       │               46,XX → Pure gonadal dysgenesis
        │       │               46,XY → Swyer syndrome
        │       │
        │       └─ FSH/LH LOW → Hypothalamic/Pituitary
        │               └─ MRI brain → Kallmann / IHH / Tumor
        │
        └─ BREASTS PRESENT (Estrogen present)
                │
                ├─ UTERUS ABSENT (USS)
                │       └─ Karyotype:
                │               46,XX → MRKH syndrome
                │               46,XY → Complete AIS
                │               (testosterone to differentiate)
                │
                └─ UTERUS PRESENT (USS)
                        └─ Outflow tract obstruction
                                ├─ Imperforate hymen (bulging introitus)
                                ├─ Transverse vaginal septum (MRI)
                                └─ Cervical agenesis (MRI)

---

📊 Summary Table of Causes by Branch

---

---

Scenarios Where FSH is High

---

🔬 Why FSH Rises

• Estradiol + Inhibin B (from granulosa cells / Sertoli cells) suppress FSH at the pituitary
• Testosterone suppresses LH predominantly

FSH is a better marker of gonadal failure than LH because it reflects loss of both estradiol AND inhibin B feedback, and it is less variable. (Harrison's, p. 11055)

---

📋 All Scenarios Where FSH is Elevated

---

1. 🔴 Natural Menopause

• Most common physiological cause of high FSH
• Ovarian follicular reserve depleted → ↓ estradiol + ↓ inhibin B → FSH rises markedly
• FSH >25–40 IU/L on two occasions confirms menopause
• Average age: 51 years
• LH also elevated; estradiol low

---

2. 🟠 Premature Ovarian Insufficiency (POI)

• Ovarian failure before age 40; accounts for ~10% of secondary amenorrhea
• FSH >25 IU/L on two measurements ≥4 weeks apart (in the presence of amenorrhea ≥4 months)
• AMH very low; estradiol low
• May wax and wane — serial measurements needed to confirm
• Causes include:

---

3. 🟡 Gonadal Dysgenesis

Turner Syndrome (45,X)

• Streak gonads with no functional follicles → no estrogen/inhibin → markedly elevated FSH from birth
• FSH very high in infancy, falls slightly in childhood, rises again at expected puberty
• Primary amenorrhea, absent breast development, short stature, typical stigmata

Pure Gonadal Dysgenesis

• 46,XX gonadal dysgenesis — normal female phenotype, streak gonads, high FSH
• 46,XY gonadal dysgenesis (Swyer syndrome) — female phenotype, XY karyotype, streak gonads → high FSH; gonads must be removed (gonadoblastoma risk)

Mosaic Turner (45,X/46,XX)

• Variable gonadal function; FSH may be elevated or normal depending on residual ovarian tissue

---

4. 🟢 Post-Oophorectomy / Surgical Castration

• Bilateral oophorectomy (surgical menopause) → abrupt loss of ovarian feedback
• FSH rises rapidly within days; can reach very high levels (>100 IU/L)
• Sudden onset of menopausal symptoms

---

5. 🔵 Iatrogenic Gonadal Damage

---

6. ⚫ Primary Testicular Failure (Males)

In men, FSH reflects tubular/Sertoli cell integrity (inhibin B). LH and testosterone reflect Leydig cell function. FSH can be elevated while LH + testosterone remain normal (isolated tubular failure).

---

7. 🟣 Enzyme Deficiencies Affecting Steroidogenesis

---

8. 🔶 Perimenopause (Menopausal Transition)

• FSH begins rising years before the final menstrual period
• Irregular cycles; FSH may fluctuate between normal and elevated
• Inhibin B falls first → FSH rises selectively (LH often still normal initially)
• FSH >10–12 IU/L on day 3 suggests diminished ovarian reserve in reproductive-age women

---

9. 🔷 Diminished Ovarian Reserve (DOR)

• Not complete ovarian failure, but reduced follicular pool
• Day 3 FSH >10 IU/L = marker of poor ovarian reserve
• Used in infertility assessment alongside AMH and antral follicle count (AFC)
• Associated with poor IVF response

---

10. 🟤 Gonadotropin-Secreting Pituitary Tumors

• FSH-secreting adenomas (rare) → autonomous FSH secretion independent of GnRH feedback
• May cause ovarian hyperstimulation, large multicystic ovaries, elevated estradiol
• Paradoxically: high FSH + high estradiol (not low) — distinguishes from gonadal failure
• Diagnosed on MRI pituitary + elevated α-subunit

---

11. 🩶 Physiological States

---

📊 Quick Reference Summary

---

🔑 Key Clinical Pearl

In gonadal failure (the most common cause): FSH is high + sex steroids are LOW. In FSH-secreting tumor: FSH is high + sex steroids are HIGH. This distinction is critical and prevents misdiagnosis.

---

Causes of Premature Ovarian Failure (Primary Ovarian Insufficiency)

📌 Definition & Terminology

• Premature Ovarian Insufficiency (POI) — preferred modern term — refers to loss of ovarian function before age 40 (Harrison's, p. 11055)
• Premature menopause = permanent cessation of menses before 40
• Early menopause = cessation between ages 40–45
• POI differs from premature menopause in that ovarian function may wax and wane — intermittent ovulation and even spontaneous pregnancy can occur in ~5–10% of cases
• Accounts for ~10% of secondary amenorrhea
• Causes span genetic, autoimmune, toxic, metabolic, and iatrogenic categories (Hormone Therapy Position Statement 2022, p. 7)

---

🔬 Pathophysiology

---

📋 Causes of Premature Ovarian Failure

---

1. 🧬 Genetic Causes (~25–30% of POI)

A. Chromosomal Abnormalities

B. Single Gene Mutations

---

2. 🛡️ Autoimmune Causes (~5–30% of POI)

• Most common identifiable cause of POI in reproductive-age women
• Two subtypes:

A. Autoimmune Oophoritis

• Lymphocytic infiltration of theca cells (not granulosa initially)
• Anti-steroidogenic cell antibodies (anti-21-hydroxylase, anti-17α-hydroxylase, anti-side-chain cleavage enzyme)
• Anti-ovarian antibodies (less specific)
• Often part of Autoimmune Polyglandular Syndrome (APS):

• Adrenal antibodies (anti-21-hydroxylase) are the best marker — positive in ~4% of POI but predict autoimmune oophoritis

B. Associated Autoimmune Conditions

---

3. ☢️ Iatrogenic Causes

A. Chemotherapy

• Alkylating agents — most gonadotoxic:
  • Cyclophosphamide, busulfan, chlorambucil, melphalan, procarbazine
  • Destroy primordial follicles directly
• Risk factors: older age, higher cumulative dose, combined regimens
• Platinum compounds (cisplatin), taxanes — intermediate risk
• Methotrexate, vincristine — low risk
• Fertility preservation (oocyte/embryo cryopreservation, ovarian tissue cryopreservation) recommended before chemotherapy

B. Radiotherapy

• Dose-dependent follicular destruction:

• Whole-body irradiation (bone marrow transplant conditioning) → very high POI risk
• Cranial irradiation → hypothalamic-pituitary damage (central, not primary ovarian)
• Ovarian transposition (oophoropexy) can reduce radiation exposure

C. Surgery

• Bilateral oophorectomy → immediate surgical menopause
• Unilateral oophorectomy → accelerates decline in ovarian reserve; earlier menopause
• Ovarian cystectomy (especially for endometrioma) → removes healthy ovarian cortex → reduces reserve
• Hysterectomy without oophorectomy → may impair ovarian blood supply → earlier POI

---

4. ⚗️ Metabolic / Enzyme Deficiency Causes

---

5. 🦠 Infectious Causes (Rare)

---

6. 🔌 FSH Receptor / Gonadotropin Resistance

• Inactivating FSH receptor mutations (FSHR gene) — follicles present but cannot respond to FSH → arrested folliculogenesis
  • "Savage syndrome" or ovarian resistance syndrome
  • High FSH, normal-sized ovaries with arrested follicles on biopsy
  • More common in Finnish population (Ala189Val mutation)
• LH receptor mutations — LH resistance; secondary amenorrhea
• Antibodies against FSH receptor — postulated in some autoimmune POI cases

---

7. 🧠 Syndromic / Systemic Associations

---

8. ❓ Idiopathic (~50–75% of Cases)

• Despite thorough investigation, no identifiable cause is found in the majority
• Likely represents undiscovered genetic variants, oligogenic inheritance, or gene-environment interactions
• Research ongoing with whole-exome/genome sequencing identifying new candidate genes

---

📊 Summary by Category

---

🔍 Investigations Recommended in All POI Patients

---

⚠️ Key Clinical Points

• FMR1 premutation must always be screened — has implications for genetic counseling (risk of Fragile X in offspring) and for sisters/daughters of the proband
• Adrenal antibodies positivity warrants adrenal function testing — Addison's disease can be life-threatening if missed
• POI is not the same as menopause — spontaneous pregnancy occurs in ~5–10%; contraception still needed if pregnancy is not desired
• Hormone replacement therapy (HRT) is recommended until the natural age of menopause (~51 years) to protect bone, cardiovascular, and neurological health

---

🔬 Evidence & Mechanisms

1. Accelerated Follicle Recruitment During Each Pregnancy

• Each pregnancy involves suspension of ovulation but not suspension of follicular atresia
• Primordial follicles continue to undergo atresia even during pregnancy
• However, during pregnancy, FSH is suppressed (by placental estrogen/progesterone/inhibin) → theoretically follicle recruitment is reduced → this is actually somewhat protective
• The net effect is debated

2. Postpartum Hormonal Disruption

• Each postpartum period involves a surge in FSH (as pituitary suppression is lifted) → accelerated follicle recruitment in the postpartum window
• Breastfeeding-associated hyperprolactinemia suppresses GnRH → intermittent FSH fluctuations during lactation may affect follicular dynamics

3. Repeated Physiological Stress on Ovarian Vasculature

• Multiple pregnancies may cause cumulative microangiopathic changes in ovarian blood supply
• Reduced ovarian perfusion → accelerated follicular atresia

4. Nutritional Depletion

• Grand multiparity (≥5 pregnancies) in resource-limited settings → chronic nutritional deficiency, micronutrient depletion (zinc, folate, iron) → may impair follicular health and mitochondrial function in oocytes

---

📊 What the Data Shows

---

🧭 Conclusion

• Grand multiparity (≥5) in the context of poor nutrition, short inter-pregnancy intervals, and prolonged lactation may contribute to earlier ovarian reserve depletion
• It is best viewed as a modifying/contributing factor that accelerates an already ongoing biological process, rather than an independent etiology
• In clinical practice, when evaluating POI in a multiparous woman, other causes (genetic, autoimmune, iatrogenic) should still be systematically excluded before attributing it to parity alone

---

Fibroid (Uterine Leiomyoma) Management by Indication

📌 Background

• Symptoms (heavy bleeding, pressure, pain, infertility)
• Fibroid characteristics (size, number, location — FIGO classification)
• Patient's reproductive wishes
• Age and proximity to menopause

---

📍 FIGO Classification of Fibroids (Location)

---

🗂️ Management by Indication

---

1. 🟢 Asymptomatic Fibroids

• No treatment required in most cases
• Annual surveillance with pelvic USS
• Reassurance — fibroids regress spontaneously after menopause
• Indications to intervene despite no symptoms:
  • Rapid growth (raises concern for leiomyosarcoma — rare, ~0.5%)
  • Size >10–12 cm causing silent ureteric compression
  • Significant distortion of uterine cavity before planned IVF

---

2. 🔴 Heavy Menstrual Bleeding (HMB)

🔹 Medical Management (First-line, especially if fertility desired or surgery declined)

🔹 Surgical / Interventional Management

---

3. 🟡 Pelvic Pressure / Bulk Symptoms

Management:

• Surgical approach chosen based on fibroid size, number, location, and patient preference
• Abdominal myomectomy preferred for very large (>10 cm) or multiple (>3–4) fibroids
• Laparoscopic myomectomy for ≤3–4 fibroids of moderate size (<8–10 cm)

---

4. 🟠 Dysmenorrhoea / Pelvic Pain

---

5. 🔵 Fibroids and Infertility / Recurrent Miscarriage

Classification-Based Approach:

Key Points:

• Hysteroscopic myomectomy is gold standard for submucosal fibroids before IVF
• After abdominal/laparoscopic myomectomy, recommend 3–6 months delay before attempting conception (uterine scar healing)
• UAE and MRgFUS — generally not recommended when fertility is desired (reduced endometrial blood flow, risk of premature ovarian failure with UAE)
• GnRH agonists preoperatively reduce fibroid size but do not improve fertility outcomes independently

---

6. 🟣 Fibroids in Pregnancy

---

7. ⚫ Fibroid with Anaemia

• Often secondary to chronic HMB
• Preoperative optimisation:
  • Iron supplementation (oral or IV ferric carboxymaltose)
  • GnRH agonist for 3 months → induces amenorrhea → allows haemoglobin recovery + fibroid shrinkage → safer surgery
  • Blood transfusion if Hb critically low before urgent surgery
• Cell salvage during myomectomy/hysterectomy

---

📊 Management Summary by Indication

---

🔑 Decision-Making Principles

Symptomatic fibroid
        │
        ├─ Fertility desired?
        │       YES → Medical suppression → Myomectomy (route by fibroid type)
        │       NO  → Medical → UAE / Ablation → Hysterectomy
        │
        ├─ Submucosal?
        │       → Hysteroscopic myomectomy (regardless of fertility wish)
        │
        ├─ Near menopause (<5 years)?
        │       → Medical management / GnRH agonist to bridge to natural regression
        │
        └─ High surgical risk?
                → UAE / MRgFUS / GnRH agonist long-term

• Hysterectomy is the only truly curative option — recurrence impossible
• Myomectomy carries a ~30% recurrence rate at 10 years; higher with multiple fibroids
• UAE — ~20% require further intervention within 5 years
• MRgFUS — emerging; best for single, accessible, T2-hypointense fibroids (Bailey & Love's, p. 1607)

---

Clinical Analysis: 47-Year-Old with Acute Urinary Retention + 8×8cm Posterior Wall Fibroid

---

🔍 Understanding the Scenario

Why is a Posterior Wall Fibroid Causing AUR?

1. Uterine retroversion/retroflexion — posterior fibroid tips the uterus forward and downward → cervix displaced anteriorly → urethral kinking/compression at the bladder neck
2. Pelvic mass effect — 8×8 cm fibroid occupies significant pelvic space → compresses bladder trigone and urethra indirectly
3. Uterine incarceration — gravid/enlarged uterus becomes incarcerated in the pelvis → urethral obstruction (same mechanism as incarcerated retroverted uterus in pregnancy)

---

🚨 Step 1 — Immediate Emergency Management

Urethral Catheterisation (Immediate)

• Insert indwelling Foley catheter (14–16 Fr)
• Drain slowly — avoid rapid decompression of >500 mL at a time
  • Risk of decompression haematuria and post-obstructive diuresis if drained too rapidly
  • Clamp catheter every 30 minutes or use controlled drainage
• Monitor urine output hourly after catheterisation
• Send urine for MC&S (exclude concurrent UTI)

Monitor for Post-Obstructive Diuresis

• Common after prolonged high-pressure retention
• Monitor fluid balance, electrolytes (U&E), creatinine
• IV fluid replacement if diuresis >200 mL/hour

---

🔬 Step 2 — Investigations

---

🎯 Step 3 — Definitive Management

The Best Management Option: Total Hysterectomy

---

Why Not Other Options?

---

📋 Surgical Plan

Preoperative Optimisation (While Catheterised)

Surgical Approach

---

🗓️ Management Timeline

Day 0 (Presentation)
│
├─ Immediate: Urethral catheterisation → controlled bladder drainage
├─ Monitor post-obstructive diuresis
├─ Blood tests, MRI pelvis, renal function
│
Weeks 1–4
├─ Correct anaemia (iron ± transfusion)
├─ Consider GnRH agonist depot injection (if surgery to be delayed)
├─ Urology review if renal function impaired
├─ Counsel patient regarding hysterectomy
│
Weeks 4–8
└─ Total Abdominal Hysterectomy
   └─ Intraoperative ureteric identification
   └─ Ovarian conservation decision
   └─ Remove catheter post-op once voiding confirmed

---

⚠️ Special Considerations

• Leiomyosarcoma — rare (~0.5%) but must be considered for rapidly growing large fibroid; MRI features (heterogeneous signal, irregular margins, central necrosis) raise suspicion; final diagnosis on histology post-hysterectomy
• Ureteric injury risk — posterior fibroid displaces ureters medially; always identify ureters before clamping uterine vessels
• Post-op voiding trial — remove catheter 24–48 hours post-op; perform voiding trial; ensure residual volume <150 mL before discharge

---

✅ Summary Answer

The best management for this 47-year-old with AUR (1500 mL) caused by an 8×8 cm posterior uterine fibroid is:

1. Immediate: Urethral catheterisation for bladder decompression
2. Short-term: Investigate, correct anaemia, MRI pelvis, optimise for surgery
3. Definitive: Total Abdominal Hysterectomy — curative, appropriate for her age, eliminates the obstructing mass permanently, and avoids the limitations and recurrence risk of all conservative options

---

Indications for Myomectomy vs Hysterectomy in Fibroids

🔑 Core Principle

The single most important differentiating factor is whether the patient desires future fertility.

• Fertility desired → Myomectomy
• Family complete / uterus not desired → Hysterectomy

---

✂️ MYOMECTOMY

Indications

1. 🤰 Fertility Preservation (Primary Indication)

• Woman desires future pregnancy
• Fibroids causing infertility — particularly:
  • Submucosal fibroids distorting uterine cavity (FIGO 0, 1, 2)
  • Large intramural fibroids (>4–5 cm) distorting cavity
  • Fibroids associated with recurrent implantation failure in IVF
  • Fibroids associated with recurrent miscarriage
• Hysteroscopic myomectomy before IVF significantly improves implantation rates

2. 🩸 Heavy Menstrual Bleeding — Uterus to be Preserved

• Significant HMB unresponsive to medical management
• Patient declines hysterectomy or is not yet ready
• Younger patient who wishes to retain uterus even if fertility not immediately desired
• Submucosal fibroid causing HMB → hysteroscopic myomectomy

3. 💊 Failed or Unsuitable Medical Management

• Symptoms persist despite adequate medical therapy (tranexamic acid, LNG-IUS, GnRH agonists)
• Patient intolerant of medical treatment
• Medical therapy contraindicated

4. 📏 Symptomatic Fibroids with Uterine Preservation Desired

• Pelvic pressure/bulk symptoms from large fibroid(s)
• Urinary symptoms (frequency, retention) caused by fibroid
• Pelvic pain / dysmenorrhoea unresponsive to analgesia
• Patient requests uterus preservation on personal, cultural, or religious grounds

5. 🚑 Pedunculated Fibroid Torsion

• Acute surgical emergency
• Pedunculated subserosal fibroid with torsion → laparoscopic/open myomectomy

6. 📐 Specific Fibroid Characteristics Suitable for Myomectomy

• Solitary or limited number of fibroids (ideally ≤3–4)
• Well-defined, accessible location
• Size amenable to chosen surgical route

7. 🔲 Pre-IVF / Pre-Conception Optimisation

• Submucosal or cavity-distorting fibroids identified during infertility workup
• Hysteroscopic myomectomy recommended before embryo transfer

---

Routes of Myomectomy

---

Contraindications to Myomectomy

• Suspected malignancy (leiomyosarcoma) — hysterectomy preferred
• Very large uterus (>20 weeks size) — hysterectomy often safer
• Desire for permanent solution — hysterectomy more appropriate
• Coexisting uterine/endometrial pathology requiring hysterectomy

---

Post-Myomectomy Considerations

• Delay conception 3–6 months after open/laparoscopic myomectomy (scar healing)
• Caesarean section may be recommended if deep myometrial incision made (risk of uterine rupture in labour)
• Recurrence rate: ~30% at 10 years; higher with multiple fibroids, younger age, Black ethnicity

---

🏥 HYSTERECTOMY

Indications

1. ✅ Family Complete / No Desire for Future Fertility (Primary Indication)

• Symptomatic fibroids in a woman who has completed her family
• No desire for uterine preservation
• Most common indication globally for hysterectomy

2. 🩸 Severe / Refractory Heavy Menstrual Bleeding

• HMB causing significant iron-deficiency anaemia unresponsive to:
  • Medical therapy
  • Conservative surgical procedures (hysteroscopic myomectomy, endometrial ablation)
• Quality of life severely impaired
• Recurrent HMB after previous myomectomy

3. 📏 Severe Bulk / Pressure Symptoms

• Large uterus (equivalent to ≥14–16 weeks size) causing:
  • Urinary retention or obstructive uropathy (as in the previous case)
  • Bilateral hydronephrosis / ureteric compression
  • Severe urinary frequency/urgency unresponsive to other treatment
  • Significant bowel compression → constipation/tenesmus
  • Venous obstruction → lower limb oedema, varicosities

4. 🔁 Recurrence After Myomectomy

• Symptomatic fibroid recurrence after previous myomectomy
• Multiple recurrences
• Patient no longer desires further uterus-preserving attempts

5. ❌ Failed Conservative / Interventional Treatments

• Failure of:
  • Medical management
  • UAE (uterine artery embolisation)
  • MRgFUS
  • Endometrial ablation
  • Previous myomectomy
• Persistent or worsening symptoms

6. 🔴 Suspected or Confirmed Leiomyosarcoma

• Rapid fibroid growth (especially post-menopausal)
• MRI features suspicious for sarcoma (heterogeneous signal, irregular borders, central necrosis)
• Elevated LDH
• Total hysterectomy mandatory — morcellation contraindicated

7. 🧩 Coexisting Uterine Pathology

• Fibroids + endometrial hyperplasia/carcinoma
• Fibroids + adenomyosis causing refractory dysmenorrhoea/HMB
• Fibroids + cervical dysplasia/carcinoma
• Fibroids + endometriosis requiring definitive treatment
• Fibroids + uterine prolapse (vaginal hysterectomy preferred)

8. ⚕️ High Surgical Risk Favouring Single Definitive Procedure

• Multiple comorbidities making repeat surgeries hazardous
• Patient preference for one definitive operation
• Obesity, previous multiple pelvic surgeries, anticipated difficult adhesions

9. 🔢 Multiple / Diffuse Fibroids

• Too numerous for myomectomy to be practical
• Diffuse leiomyomatosis (entire myometrium replaced by fibroids)
• Would leave an unacceptably thin or structurally compromised uterus after removal

10. 👵 Perimenopausal / Postmenopausal Women

• Symptomatic fibroids in women approaching or past menopause
• Avoids multiple procedures; fibroids will not regress fast enough to relieve current symptoms
• Postmenopausal fibroid growth → always suspect sarcoma → hysterectomy

---

Types of Hysterectomy in Fibroid Management

Routes of Hysterectomy

---

📊 Side-by-Side Comparison

---

🧭 Decision Algorithm

Symptomatic Fibroid — Surgical Management Needed
                │
                ├─ Fertility desired?
                │       │
                │       YES → MYOMECTOMY
                │               ├─ Submucosal → Hysteroscopic
                │               ├─ Intramural/subserosal → Laparoscopic / Open
                │               └─ Counsel re: recurrence, CS in future pregnancy
                │
                └─ NO (Family complete / uterus not desired)
                        │
                        ├─ Coexisting pathology? → Hysterectomy + address pathology
                        ├─ Failed previous myomectomy? → Hysterectomy
                        ├─ Suspected sarcoma? → Hysterectomy (open, no morcellation)
                        ├─ Multiple/diffuse fibroids? → Hysterectomy
                        ├─ Large uterus with obstructive complications? → Hysterectomy
                        └─ HYSTERECTOMY
                                ├─ Route: Abdominal / Laparoscopic / Vaginal
                                └─ BSO vs. ovarian conservation based on age/risk

---

⚠️ Key Points to Remember

• Myomectomy ≠ cure — recurrence rate 30% at 10 years; counsel patients accordingly
• Hysterectomy = only cure — but irreversible; must confirm no future fertility desired
• Suspected sarcoma → open hysterectomy; never morcellate (risk of disseminating malignancy)
• GnRH agonist preoperatively (3 months) for both procedures — reduces fibroid size, vascularity, intraoperative blood loss, and corrects anaemia
• Post-myomectomy mode of delivery depends on depth of myometrial incision — deep entry into cavity → elective CS recommended

---

HMB + Severe Migraine with Normal TVUSS — Management

🔍 Clinical Problem Analysis

---

⚠️ The Critical Issue: Migraine + Estrogen = Contraindicated

WHO / UKMEC Classification for Migraine

Why Estrogen is Dangerous in Migraine

• Estrogen promotes a prothrombotic state — increases coagulation factors, decreases antithrombin III
• Migraine with aura is an independent risk factor for ischaemic stroke (RR ~2–4×)
• Combining estrogen + migraine with aura → multiplicative stroke risk (~8× above baseline)
• Estrogen fluctuations also trigger migraines (menstrual migraine — estrogen withdrawal)
• Therefore:
  • COCP, patch, vaginal ring, combined injectable → all contraindicated
  • Even HRT with estrogen should be used with extreme caution

---

✅ Treatment Options — Safe and Effective

1. Non-hormonal options — safe regardless of migraine
2. Progestogen-only options — UKMEC 2 (benefits outweigh risks)

---

🥇 FIRST LINE — Levonorgestrel Intrauterine System (LNG-IUS / Mirena)

LNG-IUS (Mirena) is the single most appropriate treatment — addresses HMB effectively, is safe in migraine, and avoids estrogen entirely.

---

🥈 SECOND LINE — Non-Hormonal Medical Management

A. Tranexamic Acid

B. NSAIDs (Mefenamic Acid / Ibuprofen)

C. Tranexamic Acid + NSAIDs Combined

• Complementary mechanisms
• Can be used together for additive effect on HMB
• Both safe in migraine

---

🥉 THIRD LINE — Progestogen-Only Hormonal Options

A. Oral Norethisterone (High Dose)

B. Depo-Provera (DMPA — Depot Medroxyprogesterone Acetate)

C. Progestogen-Only Pill (POP — Desogestrel 75 mcg)

D. Etonogestrel Implant (Nexplanon)

---

🔷 GnRH Agonists (Adjunct / Bridge)

---

🔴 What to AVOID

---

📋 Management Algorithm for This Patient

HMB + Severe Migraine + Normal TVUSS
              │
              ├─ Is migraine WITH AURA?
              │       YES → Estrogen ABSOLUTELY contraindicated (UKMEC 4)
              │       NO  → Estrogen relatively contraindicated (UKMEC 3)
              │
              ├─ FIRST LINE:
              │       LNG-IUS (Mirena) ← BEST OPTION
              │       Progestogen-only; 90-95% ↓ blood loss; safe in migraine
              │
              ├─ If LNG-IUS declined / awaiting insertion:
              │       Tranexamic acid (during menses) +/- Mefenamic acid
              │       → Non-hormonal; dual benefit (HMB + menstrual migraine)
              │
              ├─ If hormonal supplementation needed:
              │       Progestogen-only options (norethisterone, DMPA)
              │       Avoid all estrogen-containing preparations
              │
              ├─ Persistent / failed medical management:
              │       Endometrial ablation (if family complete)
              │       Hysterectomy (definitive; last resort)
              │
              └─ Address migraine separately:
                      Triptans for acute attacks
                      Propranolol / topiramate / amitriptyline for prophylaxis
                      (Topiramate caution if pregnancy possible)

---

🔗 Additional Considerations

Menstrual Migraine

• Many women with severe migraine have menstrual migraine — attacks triggered by estrogen withdrawal at menstruation
• LNG-IUS can help by eliminating menstruation → removes estrogen-withdrawal trigger → may reduce migraine frequency
• Continuous progestogen (DMPA, implant) achieving amenorrhoea → eliminates hormonal fluctuation trigger

Iron Deficiency Anaemia

• Check FBC, ferritin, iron studies
• If anaemic → oral iron supplementation alongside HMB treatment
• LNG-IUS will correct anaemia over time as bleeding reduces

Investigate Migraine Properly

• Confirm whether migraine is with or without aura — changes UKMEC category and urgency of avoiding estrogen
• Neurology referral if poorly controlled
• Ensure adequate migraine prophylaxis in place

---

✅ Summary

---

Postmenopausal Bleeding (PMB) — Step-by-Step Investigation

📌 Definition

---

⚠️ Key Principle

PMB = Endometrial cancer until proven otherwise. ~10% of women with PMB have endometrial cancer. The majority (~90%) have benign causes — but malignancy must be excluded first in every case.

---

🔢 Causes of PMB (Differential Diagnosis)

---

🔢 Step-by-Step Investigation

---

✅ STEP 1 — History

• Duration, amount, frequency, colour (fresh red vs. brown/dark)
• Single episode vs. recurrent
• Associated symptoms: discharge (offensive → pyometra), pelvic pain, weight loss, bloating

• Combined OCP use
• Multiparity
• Progestogen-containing HRT

• HRT type (combined vs. unopposed estrogen)
• Tamoxifen
• Anticoagulants
• Antipsychotics (↑ prolactin)

---

✅ STEP 2 — Physical Examination

• Atrophic vaginitis: pale, thin, dry vaginal walls, loss of rugae, petechiae — reassuring
• Cervical polyp/mass: visible on speculum — may explain bleeding
• Uterine enlargement + tenderness: suggests pyometra or carcinoma

---

✅ STEP 3 — Transvaginal Ultrasound (TVUSS)

Endometrial Thickness (ET) Measurement:

Additional TVUSS Assessment:

• Endometrial appearance: homogeneous vs. heterogeneous, polypoidal lesions, echogenic foci (calcification), fluid in cavity (haematometra/pyometra)
• Myometrium: invasion depth if mass visible; adenomyosis
• Ovaries: size, morphology, masses (estrogen-secreting tumour)
• Adnexa: free fluid, masses
• Cervical canal: stenosis, mass

TVUSS Findings and Their Implications:

---

✅ STEP 4 — Endometrial Biopsy (Histological Diagnosis)

• ET >4 mm on TVUSS
• Persistent PMB even if ET ≤4 mm (recurrent bleeding always warrants biopsy)
• Abnormal endometrial appearance on TVUSS regardless of thickness
• Unable to measure ET adequately on TVUSS
• High-risk patient (Lynch syndrome, tamoxifen, obesity)

Methods:

When Pipelle is Insufficient → Proceed to Hysteroscopy:

• Inadequate sample on pipelle
• Cervical stenosis preventing pipelle entry
• Focal lesion on TVUSS (pipelle may miss)
• Persistent PMB despite negative pipelle
• Patient anxiety / office procedure not tolerated

---

✅ STEP 5 — Hysteroscopy

---

✅ STEP 6 — Laboratory Investigations

---

✅ STEP 7 — Further Imaging (If Endometrial Cancer Confirmed)

---

🗺️ Investigation Algorithm

Postmenopausal Bleeding
          │
          ├─ History + Examination
          │       ├─ Speculum: cervical polyp/mass → refer colposcopy/gynaecology
          │       └─ Atrophic vaginitis → note but still investigate
          │
          ├─ TVUSS (First-line)
          │       │
          │       ├─ ET ≤4 mm + normal appearance
          │       │       └─ Single episode → Reassure + watchful waiting
          │       │           Recurrent PMB → Pipelle biopsy anyway
          │       │
          │       ├─ ET >4 mm OR abnormal appearance
          │       │       └─ ENDOMETRIAL BIOPSY (Pipelle)
          │       │               ├─ Adequate sample → Histology report
          │       │               └─ Inadequate / focal lesion → HYSTEROSCOPY
          │       │
          │       └─ Cannot visualise / technically inadequate
          │               └─ Proceed directly to HYSTEROSCOPY
          │
          ├─ Hysteroscopy + Directed Biopsy
          │       ├─ Polyp → Polypectomy + histology
          │       ├─ Suspicious endometrium → Directed biopsy
          │       └─ Normal → Reassure
          │
          └─ Histology Result
                  ├─ Benign (atrophy, polyp, simple hyperplasia) → Treat accordingly
                  ├─ Hyperplasia without atypia → Progestogen / LNG-IUS + surveillance
                  ├─ Atypical hyperplasia → Hysterectomy (high malignant potential)
                  └─ Endometrial carcinoma → Staging (MRI + CT) → MDT → Surgery

---

📊 Histological Outcomes and Management

---

🔑 Key Points

• PMB = endometrial cancer until excluded — never attribute to benign cause without investigation
• TVUSS ET ≤4 mm + single episode of PMB + no risk factors = reassure, but recurrent PMB always requires biopsy regardless of ET
• Pipelle biopsy is the workhorse outpatient test — but hysteroscopy is needed for focal lesions and failed/inadequate pipelle
• Atypical hyperplasia (EIN) → hysterectomy without delay (40–50% harbour concurrent carcinoma)
• Lynch syndrome patients → lifelong annual surveillance even without symptoms

---

Cyclical Progesterone vs. MPA for HMB in a 16-Year-Old

🔍 Understanding the Clinical Context First

Mandatory Initial Workup Before Starting Treatment

---

⚖️ The Direct Answer: Cyclical Progesterone vs. MPA

Both are progestogens — but they differ significantly in:

---

🎯 Which is Better for a 16-Year-Old?

Neither is the ideal first-line treatment in a 16-year-old with anovulatory HMB.

---

❌ Why Cyclical Progestogen (Norethisterone or MPA) is NOT the Best Choice Here

1. Mechanism mismatch — Cyclical progestogen works by opposing estrogen-driven endometrial proliferation. In anovulatory DUB, the problem IS lack of progesterone. Cyclical progestogen helps but:
   • Requires precise cycle-day timing (difficult in irregular cycles)
   • Does not address the underlying HPO axis immaturity
   • High dose norethisterone has androgen side effects problematic in a teenager (acne, weight gain)
2. DMPA (Depo-Provera injectable MPA) — not recommended as first-line in adolescents:
   • Causes significant bone mineral density (BMD) loss — critical during peak bone mass acquisition (ages 12–18)
   • WHO, ACOG, and FSRH advise caution with DMPA in adolescents under 18
   • If used, duration should be limited and calcium/vitamin D supplementation given
3. Oral MPA cyclically — acceptable but evidence for norethisterone in HMB is stronger; norethisterone 5 mg TDS (days 5–26) is better studied for HMB reduction

---

✅ Preferred Evidence-Based Options for HMB in a 16-Year-Old

🥇 FIRST LINE: Combined Oral Contraceptive Pill (COCP)

For anovulatory DUB in adolescents, COCP is the most appropriate hormonal option — addresses both the HMB and the underlying anovulatory cycle dysregulation.

---

🥇 FIRST LINE (Non-hormonal): Tranexamic Acid

---

🥇 FIRST LINE (Non-hormonal): NSAIDs (Mefenamic acid / Ibuprofen)

---

🥈 SECOND LINE: Cyclical Norethisterone (if COCP contraindicated/declined)

• Norethisterone 5 mg TDS, days 5–26 of cycle
• Better evidence for HMB reduction than MPA
• Regulates cycle
• Monitor for androgenic side effects in teenager
• Not ideal long-term due to side effect profile

---

🥈 SECOND LINE: Oral MPA cyclically (if norethisterone not tolerated)

• MPA 10–20 mg/day, days 16–26 (luteal phase supplementation)
• Better tolerated than norethisterone for some patients
• Less androgenic
• Less data specifically for HMB than norethisterone

---

⚠️ LNG-IUS (Mirena) — Consider in Selected Adolescents

---

📋 Direct Comparison Table: Cyclical Norethisterone vs. Oral MPA in a 16-Year-Old

---

🧭 Recommended Approach for This Patient

16-year-old with HMB
          │
          ├─ Exclude: Pregnancy, coagulopathy (vWD), thyroid disease
          │
          ├─ Assess severity:
          │       Mild-Moderate → Non-hormonal first
          │       Severe (Hb <10, flooding, school disruption) → Hormonal
          │
          ├─ FIRST-LINE OPTIONS:
          │       Non-hormonal: Tranexamic acid + Mefenamic acid (during menses)
          │       Hormonal: COCP (if no contraindication) → best for anovulatory DUB
          │
          ├─ IF COCP CONTRAINDICATED:
          │       Cyclical Norethisterone 5mg TDS (days 5–26) — better than MPA for HMB
          │       OR Oral MPA 10mg BD (days 16–26) — if norethisterone poorly tolerated
          │
          ├─ AVOID:
          │       DMPA (Depo-Provera) injectable — bone density loss in adolescence
          │
          ├─ IF REFRACTORY / SEVERE:
          │       LNG-IUS (Mirena)
          │       Haematology referral if coagulopathy confirmed
          │
          └─ Correct anaemia: Oral ferrous sulphate 200mg TDS

---

✅ Direct Answer to the Question

---

HMB Management in a 40-Year-Old — Cyclical Progesterone vs. MPA

🔍 Key Differences from the 16-Year-Old

---

⚠️ Step 1 — Mandatory Investigation BEFORE Treatment

At 40, never start hormonal treatment for HMB without first excluding endometrial pathology (hyperplasia/carcinoma) — especially if irregular bleeding.

---

🎯 Direct Answer: Cyclical Progesterone vs. MPA at 40

Both are now more appropriate than in the 16-year-old — but still not the best first-line options.

---

⚖️ Head-to-Head Comparison at Age 40

---

🥇 Best Options at Age 40 — Ranked

1. 🏆 LNG-IUS (Mirena) — BEST OVERALL OPTION

Still the single most effective and appropriate treatment for HMB at 40 — as at any age with a normal uterus.

---

2. COCP — Good Option if No Contraindications

---

3. Non-hormonal Options — Still Valid First-line

---

4. Cyclical Norethisterone (Days 5–26)

---

5. Oral MPA (Cyclical)

---

6. DMPA (Depo-Provera) — Now Acceptable at 40

---

7. GnRH Agonists — Bridge Only

---

📋 Decision Based on Fertility Desire

If Fertility Still Desired:

Non-hormonal: Tranexamic acid + NSAIDs (during menses)
      ↓ (if insufficient)
Cyclical Norethisterone (days 5–26) OR Oral MPA
      ↓ (if insufficient)
LNG-IUS (still safe — rapid reversal on removal)
      ↓ (if structural cause found)
Hysteroscopic polypectomy / myomectomy as appropriate

If Fertility NOT Desired (Family Complete):

LNG-IUS ← BEST FIRST-LINE (also provides contraception)
      OR
COCP (if no contraindications)
      ↓ (if declined/contraindicated)
Cyclical norethisterone / oral MPA
      ↓ (if failed)
DMPA / GnRH agonist (bridge)
      ↓ (if all medical options fail)
Endometrial ablation (family complete, normal cavity)
      ↓ (definitive)
Hysterectomy

---

📊 Summary Comparison — 16-Year-Old vs. 40-Year-Old

---

✅ Direct Answer

At 40 years, both cyclical norethisterone and oral MPA are more appropriate than at 16 (bone density not a concern; higher risk of endometrial hyperplasia needing progestogen protection).

• Norethisterone (days 5–26) is superior to MPA for HMB reduction (~80% vs. moderate)
• Oral MPA is preferred if androgenic side effects of norethisterone are a concern
• However, LNG-IUS remains the single best treatment for HMB at 40 — more effective than either oral progestogen, provides contraception, and protects the endometrium until menopause
• Investigate first — endometrial biopsy + TVUSS mandatory before starting any treatment at 40

---

Diagnosis & Management: Fixed Retroverted Uterus + POD Nodules + Deep Dyspareunia + Dysmenorrhoea

🎯 Diagnosis: Deep Infiltrating Endometriosis (DIE)

"Finding pelvic tenderness, a fixed retroverted uterus, tender uterosacral ligaments or enlarged ovaries on examination is suggestive of endometriosis. The diagnosis is more certain if deeply infiltrating nodules are found on the uterosacral ligaments or in the pouch of Douglas." (Bailey & Love's, p. 1603)

---

🔍 Clinching the Diagnosis — Feature by Feature

---

📸 Laparoscopic Appearance of DIE

---

🧬 Pathophysiology

• Uterosacral ligaments
• Pouch of Douglas / rectovaginal septum
• Ovaries (endometriomas)
• Bowel (rectosigmoid)
• Bladder
• Pelvic peritoneum

• Repeated cyclical bleeding from implants → inflammation → fibrosis → adhesion formation → uterus becomes fixed in retroversion

---

🔢 Differential Diagnosis

---

🔬 Investigations

First-Line

Gold Standard

Additional Imaging for DIE (Pre-surgical Mapping)

"A digital rectal examination should be conducted to assess for disease involving the rectosigmoid area, as well as lateral and dorsal extension suggesting involvement of the hypogastric vessels and/or nerves." (Bailey & Love's, p. 1603)

---

📊 Staging (rASRM Classification)

Fixed uterus + obliterated POD + DIE nodules = Stage III–IV endometriosis

---

💊 Management

"Management options include pharmacological, non-pharmacological and surgical treatments. Endometriosis is an oestrogen-dependent condition. Most drug treatments work by suppressing ovarian function. The choice depends on the woman's preferences and priorities in terms of pain management and/or fertility." (Endometriosis: Diagnosis and Management, p. 30)

1. Is fertility desired?
2. Is pain the primary concern or infertility or both?

---

🔷 A. If FERTILITY DESIRED + PAIN

Medical (Temporising — does not restore fertility)

⚠️ All hormonal treatments suppress ovulation — they are contraceptive by nature. They do NOT improve fertility and should not be used when actively trying to conceive.

Surgical (Definitive for Fertility + Pain)

• Excision > ablation for DIE — ablation misses depth of infiltration
• Complete excision at one operation preferred — reduces recurrence
• Multidisciplinary team (gynaecology, colorectal, urology) for complex DIE
• Postoperative hormonal suppression reduces recurrence

• Spontaneous pregnancy rates improve after laparoscopic excision of Stage III–IV disease
• If natural conception not achieved within 6–12 months post-surgery → IVF
• IVF may be primary approach in severe DIE with poor ovarian reserve (AMH low)

---

🔷 B. If FERTILITY NOT DESIRED + PAIN MANAGEMENT

Medical (Long-term Suppression)

Surgical

---

📋 Specific Management Plan for THIS Patient (35-year-old, DIE)

35-year-old — Fixed retroverted uterus + POD nodules + DIE symptoms
              │
              ├─ INVESTIGATIONS:
              │       TVUSS → endometriomas, POD obliteration
              │       MRI pelvis → DIE mapping (bowel, bladder, uterosacral)
              │       CA-125
              │       Assess ovarian reserve (AMH, AFC) — fertility planning
              │       DRE → rectovaginal nodule assessment
              │
              ├─ FERTILITY DESIRED?
              │       │
              │       YES → Laparoscopic excision of DIE
              │               + adhesiolysis + restore anatomy
              │               + cystectomy if endometrioma present
              │               → Attempt natural conception 6–12 months
              │               → IVF if not achieved
              │               → Post-surgical: hormonal suppression
              │                 (COCP / progestogen) until ready to conceive
              │
              └─ FERTILITY NOT DESIRED / COMPLETE:
                      Pain management priority:
                      Dienogest / COCP / LNG-IUS (medical suppression)
                              ↓ (if inadequate)
                      Laparoscopic excision of DIE
                              ↓ (post-surgical)
                      Long-term hormonal suppression to prevent recurrence
                              ↓ (refractory / severe)
                      Hysterectomy + BSO (definitive)

---

⚠️ Special Considerations in DIE

---

✅ Summary